SignatureFD’s Structure Therapeutics GPCR Stock Holding History

SignatureFD’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.82K	Sell	100 -6,550	-98%	-$448K	﹤0.01%	2790
2025 Q4	$463K	Hold	6,650	–	–	0.01%	634
2025 Q3	$186K	Hold	6,650	–	–	﹤0.01%	995
2025 Q2	$138K	Buy	6,650 +6,550	+6,550%	+$144K	﹤0.01%	1081
2025 Q1	$1.73K	Hold	100	–	–	﹤0.01%	2916
2024 Q4	$2.71K	Hold	100	–	–	﹤0.01%	2777
2024 Q3	$4.39K	Hold	100	–	–	﹤0.01%	2613
2024 Q2	$3.93K	Hold	100	–	–	﹤0.01%	2591
2024 Q1	$4.29K	Hold	100	–	–	﹤0.01%	2585
2023 Q4	$4.08K	Hold	100	–	–	﹤0.01%	2565
2023 Q3	$5.04K	Hold	100	–	–	﹤0.01%	2492
2023 Q2	$4.16K	Hold	100	–	–	﹤0.01%	2577
2023 Q1	$2.38K	Buy	+100	New	+$2.35K	﹤0.01%	2752

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

SignatureFD's GPCR Position: Q1 2026 in Review

SignatureFD reduced its Structure Therapeutics (GPCR) stake by 98% in Q1 2026, selling an estimated $448K and leaving 100 shares worth $4.82K. The position accounts for ﹤0.01% of the portfolio, ranked #2790.

SignatureFD first reported a position in GPCR in Q1 2023 and has held it in 13 quarters since. The position peaked at $463K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

SignatureFD held 100 shares of Structure Therapeutics worth $4.82K as of Q1 2026.
SignatureFD sold 6,550 Structure Therapeutics shares in Q1 2026, an estimated $448K.
Structure Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #2790 holding.
SignatureFD first reported a position in Structure Therapeutics in Q1 2023 and has held it in 13 quarters since.
SignatureFD's Structure Therapeutics position peaked at $463K in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.